Anti-PSMA/PSCA chimeric antigen receptor T cell therapy - Shanghai Unicar-Therapy Bio-medicine Technology
Alternative Names: PD-1 silent PSMA/PSCA targeted CAR-T cell therapy - Shanghai Unicar-Therapy Bio-medicine TechnologyLatest Information Update: 01 Apr 2023
At a glance
- Originator Shanghai Unicar-Therapy Bio-medicine Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 02 Aug 2018 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in China (Parenteral) (NCT05732948)